Saheki A - Search Results

1

A novel delivery system for amphotericin B with lipid nano-sphere (LNS).

Fukui H, Koike T, Saheki A, Sonoke S, Seki J. Fukui H, et al. Among authors: saheki a. Int J Pharm. 2003 Oct 20;265(1-2):37-45. doi: 10.1016/s0378-5173(03)00404-6. Int J Pharm. 2003. PMID: 14522116

2

Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS).

Fukui H, Koike T, Saheki A, Sonoke S, Tomii Y, Seki J. Fukui H, et al. Among authors: saheki a. Int J Pharm. 2003 Sep 16;263(1-2):51-60. doi: 10.1016/s0378-5173(03)00342-9. Int J Pharm. 2003. PMID: 12954180

3

Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.

Fukui H, Koike T, Nakagawa T, Saheki A, Sonoke S, Tomii Y, Seki J. Fukui H, et al. Among authors: saheki a. Int J Pharm. 2003 Nov 28;267(1-2):101-12. doi: 10.1016/j.ijpharm.2003.08.002. Int J Pharm. 2003. PMID: 14602388

4

A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting.

Seki J, Sonoke S, Saheki A, Fukui H, Sasaki H, Mayumi T. Seki J, et al. Among authors: saheki a. Int J Pharm. 2004 Apr 1;273(1-2):75-83. doi: 10.1016/j.ijpharm.2003.12.022. Int J Pharm. 2004. PMID: 15010132

5

Lipid transfer protein transports compounds from lipid nanoparticles to plasma lipoproteins.

Seki J, Sonoke S, Saheki A, Koike T, Fukui H, Doi M, Mayumi T. Seki J, et al. Among authors: saheki a. Int J Pharm. 2004 May 4;275(1-2):239-48. doi: 10.1016/j.ijpharm.2004.02.008. Int J Pharm. 2004. PMID: 15081154

6

Effect of back pressure on emulsification of lipid nanodispersions in a high-pressure homogenizer.

Saheki A, Seki J, Nakanishi T, Tamai I. Saheki A, et al. Int J Pharm. 2012 Jan 17;422(1-2):489-94. doi: 10.1016/j.ijpharm.2011.10.060. Epub 2011 Nov 17. Int J Pharm. 2012. PMID: 22108638

7

Influence of preparation method on polynucleotide conformation and pharmacological activity of lipoplex.

Saheki A, Fukui Y, Hoshi Y, Fukui H, Seki J, Tamai I. Saheki A, et al. Int J Pharm. 2011 Mar 15;406(1-2):117-21. doi: 10.1016/j.ijpharm.2010.12.016. Epub 2010 Dec 22. Int J Pharm. 2011. PMID: 21184816 Free article.

8

Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.

Tsuji A, Saheki A, Tamai I, Terasaki T. Tsuji A, et al. Among authors: saheki a. J Pharmacol Exp Ther. 1993 Dec;267(3):1085-90. J Pharmacol Exp Ther. 1993. PMID: 8263769

9

In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

Saheki A, Terasaki T, Tamai I, Tsuji A. Saheki A, et al. Pharm Res. 1994 Feb;11(2):305-11. doi: 10.1023/a:1018975928974. Pharm Res. 1994. PMID: 8165193

10

Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters.

Tamai I, Saheki A, Saitoh R, Sai Y, Yamada I, Tsuji A. Tamai I, et al. Among authors: saheki a. J Pharmacol Exp Ther. 1997 Oct;283(1):108-15. J Pharmacol Exp Ther. 1997. PMID: 9336314

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters